Citi

Biotech

ProKidney Corp. Skyrockets 515% on Trial Data, But is it a Buy?

Shares of ProKidney Corp. (NASDAQ: PROK) soared 515% on Tuesday, triggering shockwaves across Wall Street after the company unveiled highly…

Read More »
Back to top button